The expression of glutamate transporter GLT-1 in the rat cerebral cortex is down-regulated by the antipsychotic drug clozapine

Molecular Psychiatry

Volumn 6, Issue 4, 2001, Pages 380-386

  Melone, M ^a   Vitellaro Zuccarello, L ^b   Vallejo Illarramendi, A ^c   Perez Samartin A ^c   Matute, C ^c   Cozzi, A ^d   Pellegrini Giampietro, D E ^d   Rothstein, J D ^e   Conti, F ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^d UNIVERSITY OF FLORENCE   (Italy)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glutamate; Glutamate uptake; Neuroleptics; Schizophrenia; Synaptic transmission; Transporter regulation

Indexed keywords

CLOZAPINE; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; MESSENGER RNA; NEUROLEPTIC AGENT; POTASSIUM CHLORIDE; TRITIUM; UNCLASSIFIED DRUG; VESICULAR GLUTAMATE TRANSPORTER 1;

AMINO ACID TRANSPORT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN REGION; CELL CULTURE; CONTROLLED STUDY; CULTURE MEDIUM; DOSE TIME EFFECT RELATION; ELECTROPHYSIOLOGY; FRONTAL CORTEX; IMMUNOREACTIVITY; INCUBATION TIME; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME; XENOPUS LAEVIS;

AMINO ACID TRANSPORT SYSTEM X-AG; ANIMALS; ANTIPSYCHOTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CEREBRAL CORTEX; CLOZAPINE; FEMALE; FRONTAL LOBE; GENE EXPRESSION REGULATION; GLUTAMIC ACID; MICRODIALYSIS; OOCYTES; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; RNA, MESSENGER; XENOPUS LAEVIS;

EID: 0034972585     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000880     Document Type: Article

References (48)

1. Glutamate receptor dysfunction and schizophrenia
2. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains
3. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics
4. The role of glutamate in the pathophysiology of schizophrenia
5. A glutamatergic deficiency model of schizophrenia
6. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia
7. Glutamatergic aspects of schizophrenia
8. Glutamate receptor expression in schizophrenic brain
9. Recent advances in the phencyclidine model of schizophrenia
10. Shaping excitation at glutamatergic synapses
11. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate
12. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1
13. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs
14. Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia
15. Evidence of clozapine's effectiveness in schizophrenia: A systematic review and metaanalysis of randomized trials
16. Comparison of chronic administration of haloperidol and the atypical neuroleptics, clozapine and raclopride, in an animal model of tardive dyskinesia
17. Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function
18. Radioligand labeling of pre- and postsynaptic dopamine receptors
19. Clozapine concentrations in brain regions: Relationship to dopamine metabolite increase
20. Tissue concentrations of clozapine and its metabolities in the rat
21. The doseresponse characteristics of rat oral dyskinesias with chronic haloperidol or clozapine administration
22. Chronical haloperidol and clozapine treatment in rats: Differential RNA display analysis, behavioral and serum level determination
23. EAAC1, a high-affinity glutamate transporter, is localized to neurons and astrocytes in the cerebral cortex
24. Localization of neuronal and glial glutamate transporters
25. GAT-3, a high affinity GABA plasma membrane transporter, is localized exclusively to astrocytic processes in the cerebral cortex
26. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
27. 2+ channels encoded by mRNA from the adult corpus callosum
28. Expression of glutamate transporters in rat optic nerve oligodendrocytes
29. Protection with metabotropic glutamate 1 receptor antagonists in models of ischemic neuronal death: Time-course and mechanisms
30. Cloning and expression of a rat brain L-glutamate transporter
31. Pre-clinical pharmacology of atypical antipsychotic drugs: A selective review
32. Intracellular modulation of NMDA receptor function by antipsychotic drugs
33. Clozapine. A novel antipsychotic agent
34. Antipsychotic-induced weight gain: A comprehensive research synthesis
35. Differential effect of clozapine on weight: A controlled study
36. Serum leptin levels increase rapidly after initiation of clozapine therapy
37. Chronic neuroleptic treatment alters expression of glial glutamate transporter GLT-1 mRNA in the striatum
38. Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats
39. Effects of antipsychotic drugs on extracellular dopamine levels in rate medial prefrontal cortex and nucleus accumbens
40. Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the caudate nucleus
41. The effects of clozapine on extracellular GABA levels in the prefrontal cortex of the rat: An in vivo microdialysis study
42. Neuroleptics increase c-fos expression in the forebrain: Contrasting effects of haloperidol and clozapine
43. The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: Cellular localization and pharmacological characterization
44. Induction of c-fos mRNA in rat medial prefrontal cortex by antipsychotic drugs: Role of dopamine D2 and D3 receptors
45. The cerebral cortex: A case for a common site of action on antipsychotics
46. Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats
47. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats